Functional analysis of 110 phosphorylation sites on the circadian clock protein FRQ identifies clusters determining period length and temperature compensation
G3: Genes, Genomes, Genetics · 2023
DOI: 10.1093/g3journal/jkac334 ↗Kurz gefasst
Fachartikel in der Zeitschrift G3: Genes, Genomes, Genetics, 2023. Verfasst von Bin Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH 03755, USA. Hauptthemen laut MEDLINE: Circadian Clocks, Neurospora crassa. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
In the negative feedback loop driving the Neurospora circadian oscillator, the negative element, FREQUENCY (FRQ), inhibits its own expression by promoting phosphorylation of its heterodimeric transcriptional activators, White Collar-1 (WC-1) and WC-2. FRQ itself also undergoes extensive time-of-day-specific phosphorylation with over 100 phosphosites previously documented. Although disrupting individual or certain clusters of phosphorylation sites has been shown to alter circadian period lengths to some extent, it is still elusive how all the phosphorylations on FRQ control its activity. In this study, we systematically investigated the role in period determination of all 110 reported FRQ phosphorylation sites, using mutagenesis and luciferase reporter assays. Surprisingly, robust FRQ phosphorylation is still detected even when 84 phosphosites were eliminated altogether; further mutating another 26 phosphoresidues completely abolished FRQ phosphorylation. To identify phosphoresidue(s) on FRQ impacting circadian period length, a series of clustered frq phosphomutants covering all the 110 phosphosites were generated and examined for period changes. When phosphosites in the N-terminal and middle regions of FRQ were eliminated, longer periods were typically seen while removal of phosphorylation in the C-terminal tail resulted in extremely short periods, among the shortest reported. Interestingly, abolishing the 11 phosphosites in the C-terminal tail of FRQ not only results in an extremely short period, but also impacts temperature compensation (TC), yielding an overcompensated circadian oscillator. In addition, the few phosphosites in the middle of FRQ are also found to be crucial for TC. When different groups of FRQ phosphomutations were combined intramolecularly, expected additive effects were generally observed except for one novel case of intramolecular epistasis, where arrhythmicity resulting from one cluster of phosphorylation site mutants was restored by eliminating phosphorylation at another group of sites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH 03755, USA.
ORCID-Profile: Bin Wang
Förderung
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Wang, B., Stevenson, E. L., & Dunlap, J. C. (2023). Functional analysis of 110 phosphorylation sites on the circadian clock protein FRQ identifies clusters determining period length and temperature compensation. G3: Genes, Genomes, Genetics. https://doi.org/10.1093/g3journal/jkac334
Vancouver
Wang B, Stevenson EL, Dunlap JC. Functional analysis of 110 phosphorylation sites on the circadian clock protein FRQ identifies clusters determining period length and temperature compensation. G3: Genes, Genomes, Genetics. 2023. doi:10.1093/g3journal/jkac334
BibTeX
@article{Wang2023,
author = {Wang, Bin and Stevenson, Elizabeth-Lauren and Dunlap, Jay C},
title = {Functional analysis of 110 phosphorylation sites on the circadian clock protein FRQ identifies clusters determining period length and temperature compensation},
journal = {G3: Genes, Genomes, Genetics},
year = {2023},
doi = {10.1093/g3journal/jkac334}
}
EUVIMED